Interleukin Genetics registers $15 million of stock for units offer

Rodman & Renshaw conducts sale of common shares, preferreds, warrants

By Devika Patel

Knoxville, Tenn., May 13 – Interleukin Genetics Inc. will conduct a public sale of units, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company has registered up to $15 million of stock.

The units will each consist either of common stock and warrants or series B convertible preferred shares and warrants.

Rodman & Renshaw is the bookrunner.

Proceeds will be used for commercialization of the PerioPredict genetic test, working capital and other general corporate purposes.

Interleukin, based in Waltham, Mass., is a biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.